



EXPERIMENTICA[®]
Scientific Excellence in Ocular ModelsSM

FOR IMMEDIATE RELEASE

**EXPERIMENTICA LTD. ANNOUNCES STRATEGIC EXPANSION OF MANAGEMENT
TEAM WITH THREE KEY APPOINTMENTS**

Bolsters Leadership Team, Driving Innovation and Growth in Preclinical Ocular Models.

Kuopio, Finland – April 13, 2023

Experimentica Ltd. (“Experimentica” or the “Company”), a leading contract research organization (CRO) in preclinical ophthalmic drug discovery services, today announced the appointment of three new executives to its management team. Guillaume Demarne, PharmD, will join as Chief Business Officer, Marc Cerrada-Gimenez, PhD, as Chief Technology Officer, and Jeff Jamison, PhD, as Chief Development Officer. These strategic additions reflect the company's ongoing commitment to fostering innovation, driving growth, and providing best-in-class services to its clients.

"We are delighted to recognize the outstanding contributions of Guillaume, Marc, and Jeff by bringing them to key positions within our management team," said Giedrius Kalesnykas, PhD, President and Chief Executive Officer of Experimentica. "Their collective expertise and dedication have been instrumental in our success, and we are confident that their leadership will continue to propel Experimentica forward in the preclinical ocular research space."

Guillaume Demarne, PharmD, brings over fifteen years of experience in the pharmaceutical industry, having held various leadership roles in business development,



EXPERIMENTICA[®]
Scientific Excellence in Ocular ModelsSM

fundraising, and strategy. In his new role as Chief Business Officer, Guillaume will lead Experimentica's global business development efforts, focusing on expanding the company's client base and strategic partnerships.

Marc Cerrada-Gimenez, PhD, is an accomplished scientist with a strong background in Biotechnology and data-driven research. As Chief Technology Officer, Marc will spearhead the development and implementation of innovative technologies to optimize Experimentica's preclinical research capabilities, ensuring the company remains at the forefront of scientific advancements in ocular disease modeling.

Jeff Jamison, PhD, has an extensive track record in preclinical contract research and animal model development, with a particular focus on Ophthalmology. In his position as Chief Development Officer, Jeff will oversee the expansion of Experimentica's preclinical service offerings, guiding the development of novel ocular models to help Experimentica's clients address unmet medical needs.

The addition of these seasoned professionals to the management team underlines Experimentica Ltd.'s commitment to delivering exceptional preclinical research services, while continuing to innovate and grow in the fast-paced ocular research sector.

About Experimentica Ltd.

Experimentica Ltd. is a global contract research organization (CRO) that specializes in preclinical models of ophthalmic disease. Our world-class scientists and technicians apply a comprehensive set of skills and industry experience to model ocular diseases using multiple experimental platforms, from cell culture-based systems to complex surgical techniques in preclinical models. With research laboratory operations in Kuopio (Finland), Vilnius (Lithuania), Fort Worth, Texas (USA), global representation and an industry-leading portfolio, Experimentica Ltd. delivers the highest quality science to



EXPERIMENTICA[®]
Scientific Excellence in Ocular ModelsSM

clients around the globe by helping advance their ophthalmic drug discovery and drug development portfolio.

Learn more about Experimentica at www.experimentica.com

Contact for media enquiries

Experimentica Ltd.

Guillaume Demarne, PharmD, Chief Business Officer

Email: gd@experimentica.com

Phone: +33 (0) 7 83 55 69 52